Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Tuberculosis

Free Subscription Articles published in Antimicrob Agents Chemother Retrieve available abstracts of 258 articles: HTML format

Single Articles

April 2021
1. LIN WH, Lee WT, Tsai HY, Jou R, et al
   Disputed rpoB mutations in Mycobacterium tuberculosis and tuberculosis treatment outcomes.
   Antimicrob Agents Chemother. 2021 Apr 12. pii: AAC.01573.
   PubMed     Abstract available
   
   
   March 2021
2. ARDIZZONI E, Ariza E, Mulengwa D, Mpala Q, et al
   Thin layer agar-based direct phenotypic drug-susceptibility testing on sputum in Eswatini rapidly detects Mycobacterium tuberculosis growth and rifampicin resistance, otherwise missed by WHO endorsed diagnostic tests.
   Antimicrob Agents Chemother. 2021 Mar 15. pii: AAC.02263.
   PubMed     Abstract available
   
   
   
3. MODLIN SJ, Marbach T, Werngren J, Mansjo M, et al
   Atypical Genetic Basis of Pyrazinamide Resistance in Mono-resistant Mycobacterium tuberculosis.
   Antimicrob Agents Chemother. 2021 Mar 15. pii: AAC.01916.
   PubMed     Abstract available
   
   
   February 2021
4. OMOLLO C, Singh V, Kigondu E, Wasuna A, et al
   Developing synergistic drug combinations to restore antibiotic sensitivity in drug-resistant Mycobacterium tuberculosis.
   Antimicrob Agents Chemother. 2021 Feb 22. pii: AAC.02554.
   PubMed     Abstract available
   
   
   
5. SHELTON CD, McNeil MB, Early JV, Ioerger TR, et al
   Deletion of Rv2571c confers resistance to arylamide compounds in Mycobacterium tuberculosis.
   Antimicrob Agents Chemother. 2021 Feb 22. pii: AAC.02334.
   PubMed     Abstract available
   
   
   
6. VILCHEZE C, Jacobs WR Jr
   The promises and limitations of N-acetylcysteine as a potentiator of first-line and second-line tuberculosis drugs.
   Antimicrob Agents Chemother. 2021 Feb 22. pii: AAC.01703.
   PubMed     Abstract available
   
   
   
7. LUN S, Xiao S, Zhang W, Wang S, et al
   Therapeutic potential of coumestan Pks13 inhibitors for tuberculosis.
   Antimicrob Agents Chemother. 2021 Feb 8. pii: AAC.02190.
   PubMed     Abstract available
   
   
   
8. PIETERMAN ED, van den Berg S, van der Meijden A, Svensson EM, et al
   Higher dosing of rifamycins does not increase activity against M. tuberculosis in the hollow fibre infection model.
   Antimicrob Agents Chemother. 2021 Feb 8. pii: AAC.02255.
   PubMed     Abstract available
   
   
   
9. XU J, Converse PJ, Upton AM, Mdluli K, et al
   Comparative efficacy of the novel diarylquinoline TBAJ-587 and bedaquiline against a resistant Rv0678 mutant in a mouse model of tuberculosis.
   Antimicrob Agents Chemother. 2021 Feb 1. pii: AAC.02418.
   PubMed     Abstract available
   
   
   January 2021
10. HO VQT, Verboom T, Rong MK, Habjan E, et al
    Heterologous expression of ethA and katG in Mycobacterium marinum enables the rapid identification of new prodrugs active against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2021 Jan 25. pii: AAC.01445.
    PubMed     Abstract available
    
    
    
11. KHAN MZ, Nandicoori VK
    Deletion of PknG abates reactivation of latent Mycobacterium tuberculosis in mice.
    Antimicrob Agents Chemother. 2021 Jan 19. pii: AAC.02095.
    PubMed     Abstract available
    
    
    
12. DRUSANO GL, Rogers S, Brown D, Peloquin CA, et al
    Dose-fractionation of moxifloxacin for the treatment of tuberculosis: impact of dosing interval and elimination half-life on microbial kill and resistance suppression.
    Antimicrob Agents Chemother. 2021 Jan 19. pii: AAC.02533.
    PubMed     Abstract available
    
    
    
13. ZHU H, Fu L, Wang B, Chen X, et al
    Activity of Clofazimine and TBI-166 against Mycobacterium tuberculosis, in different administration intervals in mouse tuberculosis models.
    Antimicrob Agents Chemother. 2021 Jan 11. pii: AAC.02164.
    PubMed     Abstract available
    
    
    December 2020
14. VALAFAR SJ
    A Systematic Review of Mutations Associated with Isoniazid Resistance Points to Continuing Evolution and Subsequent Evasion of Molecular Detection, and Potential for Emergence of Multidrug Resistance in Clinical Strains of Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2020 Dec 23. pii: AAC.02091.
    PubMed     Abstract available
    
    
    
15. LIN SY, Feng JY, Lee CY, Lin YC, et al
    Completion and adverse drug events of latent tuberculosis infection treatment in patients receiving dialysis: predictors and impacts of different regimens in a prospective cohort study.
    Antimicrob Agents Chemother. 2020 Dec 23. pii: AAC.02184.
    PubMed     Abstract available
    
    
    November 2020
16. VIJAY S, Nhung HN, Bao NLH, Thu DDA, et al
    Most-probable number based minimum duration of killing assay for determining the spectrum of rifampicin susceptibility in clinical M. tuberculosis isolates.
    Antimicrob Agents Chemother. 2020 Nov 30. pii: AAC.01439.
    PubMed     Abstract available
    
    
    
17. IGNATIUS EH, Abdelwahab MT, Hendricks B, Gupte N, et al
    Pretomanid Pharmacokinetics in the Presence of Rifamycins: interim Results from a Randomized Trial among Patients with Tuberculosis.
    Antimicrob Agents Chemother. 2020 Nov 23. pii: AAC.01196.
    PubMed     Abstract available
    
    
    
18. PANJASAWATWONG N, Wattanakul T, Hoglund RM, Bang ND, et al
    Population pharmacokinetic properties of anti-tuberculosis drugs in Vietnamese children with tuberculous meningitis.
    Antimicrob Agents Chemother. 2020 Nov 2. pii: AAC.00487.
    PubMed     Abstract available
    
    
    
19. GRZEGORZEWICZ AE, Lelievre J, Esquivias J, Angala B, et al
    Lack of Specificity of Phenotypic Screens for Inhibitors of the Mycobacterium tuberculosis FAS-II System.
    Antimicrob Agents Chemother. 2020 Nov 2. pii: AAC.01914.
    PubMed     Abstract available
    
    
    October 2020
20. ARUN KB, Madhavan A, Abraham B, Balaji M, et al
    Acetylation of isoniazid - a novel mechanism of isoniazid resistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2020 Oct 26. pii: AAC.00456.
    PubMed     Abstract available
    
    
    
21. WILLBY M, Chopra P, Lemmer D, Klein K, et al
    Molecular evaluation of fluoroquinolone resistance in serial Mycobacterium tuberculosis isolates from individuals diagnosed with multidrug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2020 Oct 26. pii: AAC.01663.
    PubMed     Abstract available
    
    
    
22. MALLIKAARJUN S, Chapagain ML, Sasaki T, Hariguchi N, et al
    Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Pulmonary Multidrug-Resistant Tuberculosis Patients.
    Antimicrob Agents Chemother. 2020 Oct 26. pii: AAC.01207.
    PubMed     Abstract available
    
    
    
23. WANG X, Mallikaarjun S, Gibiansky E
    Population Pharmacokinetic Analysis of Delamanid in Patients with Pulmonary Multi-Drug Resistant Tuberculosis.
    Antimicrob Agents Chemother. 2020 Oct 26. pii: AAC.01202.
    PubMed     Abstract available
    
    
    
24. RIFAT D, Li SY, Ioerger T, Shah K, et al
    Mutations in fbiD (Rv2983) as a novel determinant of resistance to pretomanid and delamanid in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2020 Oct 19. pii: AAC.01948.
    PubMed     Abstract available
    
    
    
25. SATHKUMARA HD, Hansen K, Miranda-Hernandez S, Govan B, et al
    Disparate effects of metformin on Mycobacterium tuberculosis infection in diabetic and non-diabetic mice.
    Antimicrob Agents Chemother. 2020 Oct 12. pii: AAC.01422.
    PubMed     Abstract available
    
    
    
26. VAN DER WALT ML, Shean K, Becker P, Keddy KH, et al
    Treatment outcomes and adverse drug effects of ethambutol, cycloserine and terizidone for treatment of multi-drug resistant tuberculosis in South Africa.
    Antimicrob Agents Chemother. 2020 Oct 12. pii: AAC.00744.
    PubMed     Abstract available
    
    
    September 2020
27. DRUSANO GL, Duncanson B, Scanga CA, Kim S, et al
    Developing new drugs for the therapy of Mycobacterium tuberculosis: What information do we get from pre-clinical animal models?
    Antimicrob Agents Chemother. 2020 Sep 21. pii: AAC.01376.
    PubMed     Abstract available
    
    
    
28. LI M, Nyantakyi SA, Go ML, Dick T, et al
    Resistance against membrane-inserting MmpL3 inhibitor through upregulation of MmpL5 in M. tuberculosis.
    Antimicrob Agents Chemother. 2020 Sep 21. pii: AAC.01100.
    PubMed     Abstract available
    
    
    August 2020
29. REICHMUTH ML, Homke R, Zurcher K, Sander P, et al
    Natural Polymorphisms in Mycobacterium tuberculosis Conferring Resistance to Delamanid in Drug-naive Patients.
    Antimicrob Agents Chemother. 2020 Aug 31. pii: AAC.00513.
    PubMed     Abstract available
    
    
    
30. CHIREHWA MT, Court R, De Kock M, Wiesner L, et al
    Population pharmacokinetics of cycloserine, and pharmacokinetic/pharmacodynamic target attainment, in MDR-tuberculosis patients dosed with terizidone.
    Antimicrob Agents Chemother. 2020 Aug 17. pii: AAC.01381.
    PubMed     Abstract available
    
    
    
31. ALGHAMDI WA, Al-Shaer MH, An G, Alsultan A, et al
    Population Pharmacokinetics of Linezolid in Tuberculosis Patients: Dosing Regimens Simulation and Target Attainment Analysis.
    Antimicrob Agents Chemother. 2020 Aug 10. pii: AAC.01174.
    PubMed     Abstract available
    
    
    July 2020
32. LOISEAU C, Brites D, Reinhard M, Zurcher K, et al
    HIV coinfection is associated with low fitness rpoB variants in rifampicin-resistant Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2020 Jul 27. pii: AAC.00782.
    PubMed     Abstract available
    
    
    
33. MARIOTTI S, Teloni R, de Turris V, Pardini M, et al
    Amphotericin B inhibits Mycobacterium tuberculosis infection of human alveolar type II epithelial A549 cells.
    Antimicrob Agents Chemother. 2020 Jul 13. pii: AAC.01164.
    PubMed     Abstract available
    
    
    
34. AL-SHAER MH, Martson AG, Alghamdi WA, Alsultan A, et al
    Ethionamide population pharmacokinetic model and target attainment in multidrug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2020 Jul 6. pii: AAC.00713.
    PubMed     Abstract available
    
    
    
35. VILCHEZE C, Saranathan R, Weinrick B, Jacobs WR Jr, et al
    Characterization of large deletion mutants of Mycobacterium tuberculosis selected for isoniazid resistance.
    Antimicrob Agents Chemother. 2020 Jul 6. pii: AAC.00792.
    PubMed     Abstract available
    
    
    June 2020
36. SAFI H, Lingaraju S, Ma S, Husain S, et al
    Rapidly-correcting Frameshift Mutations in the Mycobacterium tuberculosis orn Gene Produce Reversible Ethambutol Resistance and Small Colony Variant Morphology.
    Antimicrob Agents Chemother. 2020 Jun 22. pii: AAC.00213.
    PubMed     Abstract available
    
    
    
37. COHEN KA, Stott KE, Munsamy V, Manson AL, et al
    Evidence for expanding the role of streptomycin in the management of drug-resistant M. tuberculosis.
    Antimicrob Agents Chemother. 2020 Jun 15. pii: AAC.00860.
    PubMed     Abstract available
    
    
    May 2020
38. LI Y, Dong W, Lan T, Fan J, et al
    Distribution of linezolid in tuberculosis lesions in patients with spinal multidrug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2020 May 4. pii: AAC.00450.
    PubMed     Abstract available
    
    
    
39. KIM HY, Srivastava S, Kumar Ak H, Marais BJ, et al
    Optimal dose or optimal exposure? Consideration for linezolid in tuberculosis treatment.
    Antimicrob Agents Chemother. 2020 May 4. pii: AAC.00287.
    PubMed     Abstract available
    
    
    
40. DIACON AH, De Jager VR, Dawson R, Narunsky K, et al
    Reply to Kim et al., "Optimal Dose or Optimal Exposure? Consideration for Linezolid in Tuberculosis Treatment".
    Antimicrob Agents Chemother. 2020 May 4. pii: AAC.00709.
    PubMed     Abstract available
    
    
    April 2020
41. PIETERMAN ED, Sarink MJ, Sala C, Cole ST, et al
    Advanced quantification methods to improve the 18b dormancy model for assessing the activity of tuberculosis drugs in vitro.
    Antimicrob Agents Chemother. 2020 Apr 27. pii: AAC.00280.
    PubMed     Abstract available
    
    
    
42. FARAJ A, Svensson RJ, Diacon AH, Simonsson USH, et al
    Drug Effect of Clofazimine on Persisters Explains an Unexpected Increase in Bacterial Load in Patients.
    Antimicrob Agents Chemother. 2020;64.
    PubMed     Abstract available
    
    
    
43. HAYASHI M, Nishiyama A, Kitamoto R, Tateishi Y, et al
    Adduct Formation of Delamanid with NAD in Mycobacteria.
    Antimicrob Agents Chemother. 2020;64.
    PubMed     Abstract available
    
    
    
44. NARMANDAKH E, Tumenbayar O, Borolzoi T, Erkhembayar B, et al
    Genetic Mutations Associated with Isoniazid Resistance in Mycobacterium tuberculosis in Mongolia.
    Antimicrob Agents Chemother. 2020 Apr 20. pii: AAC.00537.
    PubMed     Abstract available
    
    
    March 2020
45. HARIGUCHI N, Chen X, Hayashi Y, Kawano Y, et al
    OPC-167832, a novel carbostyril derivative with potent anti-tuberculosis activity as a DprE1 inhibitor.
    Antimicrob Agents Chemother. 2020 Mar 30. pii: AAC.02020.
    PubMed     Abstract available
    
    
    
46. SEKAGGYA-WILTSHIRE C, Chirehwa M, Musaazi J, von Braun A, et al
    Erratum for Sekaggya-Wiltshire et al., "Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines?"
    Antimicrob Agents Chemother. 2020;64.
    PubMed    
    
    
    
47. ENKIRCH T, Werngren J, Groenheit R, Alm E, et al
    Systematic review of whole genome sequencing data to predict phenotypic drug resistance and susceptibility in Swedish Mycobacterium tuberculosis isolates 2016-2018.
    Antimicrob Agents Chemother. 2020 Mar 2. pii: AAC.02550.
    PubMed     Abstract available
    
    
    February 2020
48. RABIE H, Tikiso T, Lee J, Fairlie L, et al
    Abacavir exposure in children co-treated for tuberculosis with rifampicin and super-boosted lopinavir-ritonavir.
    Antimicrob Agents Chemother. 2020 Feb 18. pii: AAC.01923.
    PubMed     Abstract available
    
    
    
49. WALSH KF, McAulay K, Lee MH, Vilbrun SC, et al
    Early bactericidal activity trial of nitazoxanide for pulmonary tuberculosis.
    Antimicrob Agents Chemother. 2020 Feb 18. pii: AAC.01956.
    PubMed     Abstract available
    
    
    
50. GENGENBACHER M, Zimmerman MD, Sarathy JP, Kaya F, et al
    Tissue distribution of doxycycline in animal models of tuberculosis.
    Antimicrob Agents Chemother. 2020 Feb 10. pii: AAC.02479.
    PubMed     Abstract available
    
    
    January 2020
51. KEMPKER RR, Alghamdi WA, Al-Shaer MH, Burch G, et al
    Correction for Kempker et al., "A Pharmacology Perspective on Simultaneous Tuberculosis and Hepatitis C Treatment".
    Antimicrob Agents Chemother. 2020;64.
    PubMed    
    
    
    
52. DIACON AH, De Jager VR, Dawson R, Narunsky K, et al
    Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis.
    Antimicrob Agents Chemother. 2020 Jan 27. pii: AAC.02012.
    PubMed     Abstract available
    
    
    
53. REINGEWERTZ TH, Meyer T, McIntosh F, Sullivan J, et al
    Differential Sensitivity of Mycobacteria to Isoniazid Is Related to Differences in KatG-Mediated Enzymatic Activation of the Drug.
    Antimicrob Agents Chemother. 2020;64.
    PubMed     Abstract available
    
    
    
54. MTHIYANE T, Millard J, Adamson J, Balakrishna Y, et al
    N-acetyltransferase 2 genotypes amongst Zulu Speaking South Africans and isoniazid/N-acetyl-isoniazid pharmacokinetics during anti-tuberculosis treatment.
    Antimicrob Agents Chemother. 2020 Jan 21. pii: AAC.02376.
    PubMed     Abstract available
    
    
    
55. WASSERMAN S, Huo S, Ky K, Malig YN, et al
    CORRELATION OF LINEZOLID HAIR CONCENTRATIONS WITH PLASMA EXPOSURE IN PATIENTS WITH DRUG-RESISTANT TB.
    Antimicrob Agents Chemother. 2020 Jan 13. pii: AAC.02145.
    PubMed     Abstract available
    
    
    
56. ZHANG N, Strydom N, Tyagi S, Soni H, et al
    Mechanistic Modeling of Mycobacterium tuberculosis Infection in Murine Models for Drug and Vaccine Efficacy Studies.
    Antimicrob Agents Chemother. 2020 Jan 6. pii: AAC.01727.
    PubMed     Abstract available
    
    
    
57. JING W, Zong Z, Tang B, Wang J, et al
    Population Pharmacokinetic Analysis of Isoniazid among Pulmonary Tuberculosis Patients from China.
    Antimicrob Agents Chemother. 2020 Jan 6. pii: AAC.01736.
    PubMed     Abstract available
    
    
    December 2019
58. BJUGARD NYBERG H, Draper HR, Garcia-Prats AJ, Thee S, et al
    Population pharmacokinetics and dosing of ethionamide in children with tuberculosis.
    Antimicrob Agents Chemother. 2019 Dec 23. pii: AAC.01984.
    PubMed     Abstract available
    
    
    
59. ELINGS W, Gaur A, Blok AJ, Timmer M, et al
    beta-Lactamase of Mycobacterium tuberculosis shows dynamics in the active site that increase upon inhibitor binding.
    Antimicrob Agents Chemother. 2019 Dec 23. pii: AAC.02025.
    PubMed     Abstract available
    
    
    
60. ABDELWAHAB MT, Leisegang R, Dooley KE, Mathad JS, et al
    Population Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in South African Pregnant Women with Tuberculosis and HIV.
    Antimicrob Agents Chemother. 2019 Dec 16. pii: AAC.01978.
    PubMed     Abstract available
    
    
    November 2019
61. SUNDELL J, Bienvenu E, Birgersson S, Abelo A, et al
    Population pharmacokinetics and pharmacogenetics of ethambutol in adult patients co-infected with tuberculosis and HIV.
    Antimicrob Agents Chemother. 2019 Nov 11. pii: AAC.01583.
    PubMed     Abstract available
    
    
    October 2019
62. DONNELLAN S, Aljayyoussi G, Moyo E, Ardrey A, et al
    Intracellular pharmacodynamic modelling (PDi) is predictive of the clinical activity of fluoroquinolones against Tuberculosis.
    Antimicrob Agents Chemother. 2019 Oct 14. pii: AAC.00989.
    PubMed     Abstract available
    
    
    
63. KEMPKER RR, Alghamdi WA, Al-Shaer MH, Burch G, et al
    A Pharmacology Perspective of Simultaneous Tuberculosis and Hepatitis C Treatment.
    Antimicrob Agents Chemother. 2019 Oct 7. pii: AAC.01215.
    PubMed     Abstract available
    
    
    September 2019
64. LYONS MA
    Modeling and Simulation of Pretomanid Pharmacodynamics in Pulmonary Tuberculosis Patients.
    Antimicrob Agents Chemother. 2019 Sep 30. pii: AAC.00732.
    PubMed     Abstract available
    
    
    
65. CARRIGY NB, Larsen SE, Reese V, Pecor T, et al
    Prophylaxis of Mycobacterium tuberculosis H37Rv Infection in a Preclinical Mouse Model via Inhalation of Nebulized Bacteriophage D29.
    Antimicrob Agents Chemother. 2019 Sep 16. pii: AAC.00871.
    PubMed     Abstract available
    
    
    
66. SOMMER R, Cole ST
    Monitoring Tuberculosis Drug Activity in Live Animals by Near-Infrared Fluorescence Imaging.
    Antimicrob Agents Chemother. 2019 Sep 16. pii: AAC.01280.
    PubMed     Abstract available
    
    
    
67. HENDON-DUNN CL, Pertinez H, Marriott AAN, Hatch K, et al
    Re-growth of Mycobacterium tuberculosis populations exposed to antibiotic combinations is due to the presence of isoniazid and not bacterial growth rate.
    Antimicrob Agents Chemother. 2019 Sep 16. pii: AAC.00570.
    PubMed     Abstract available
    
    
    
68. JO KW, Kim M, Kim YJ, Lee HK, et al
    Early discontinuation of ethambutol in pulmonary tuberculosis treatment based on results of the GenoType MTBDRplus assay: A prospective, multicenter, non-inferiority randomized trial in South Korea.
    Antimicrob Agents Chemother. 2019 Sep 16. pii: AAC.00980.
    PubMed     Abstract available
    
    
    
69. YADAV R, Saini A, Agarwal P, Kapoor P, et al
    A rare D94F change in gyrA gene of multi-drug resistant Mycobacterium tuberculosis possibly contributing to an unfavorable treatment outcome.
    Antimicrob Agents Chemother. 2019 Sep 9. pii: AAC.01312.
    PubMed     Abstract available
    
    
    
70. RICHARDS JP, Cai W, Zill NA, Zhang W, et al
    Adaptation of Mycobacterium tuberculosis to biofilm growth is genetically linked to drug tolerance.
    Antimicrob Agents Chemother. 2019 Sep 9. pii: AAC.01213.
    PubMed     Abstract available
    
    
    
71. MURASE LS, de Souza JVP, Meneguello JE, Seixas FAV, et al
    Possible binding of piperine in Mycobacterium tuberculosis RNA-polymerase and rifampicin synergism.
    Antimicrob Agents Chemother. 2019 Sep 3. pii: AAC.02520.
    PubMed     Abstract available
    
    
    
72. DEMARCO VP, Ordonez AA, Klunk M, Prideaux B, et al
    Erratum for DeMarco et al., "Determination of [(11)C]Rifampin Pharmacokinetics within Mycobacterium tuberculosis-Infected Mice by Using Dynamic Positron Emission Tomography Bioimaging".
    Antimicrob Agents Chemother. 2019;63.
    PubMed    
    
    
    August 2019
73. SALINGER DH, Nedelman JR, Mendel C, Spigelman M, et al
    Daily Dosing for Bedaquiline in Patients with Tuberculosis.
    Antimicrob Agents Chemother. 2019 Aug 26. pii: AAC.00463.
    PubMed     Abstract available
    
    
    
74. TANNER L, Evans JC, Seldon R, Jordaan A, et al
    In vitro efficacies, ADME, and pharmacokinetic properties of phenoxazine derivatives active against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2019 Aug 19. pii: AAC.01010.
    PubMed     Abstract available
    
    
    
75. XIAO S, Guo H, Weiner WS, Maddox C, et al
    Revisiting the beta-lactams for tuberculosis therapy: a compound-compound synthetic lethality approach.
    Antimicrob Agents Chemother. 2019 Aug 19. pii: AAC.01319.
    PubMed     Abstract available
    
    
    
76. WANG Q, Modongo C, Allender C, Engelthaler DM, et al
    Utility of targeted, amplicon-based deep sequencing to detect resistance to first-line tuberculosis drugs in Botswana.
    Antimicrob Agents Chemother. 2019 Aug 12. pii: AAC.00982.
    PubMed     Abstract available
    
    
    
77. SALINGER DH, Subramoney V, Everitt D, Nedelman JR, et al
    Population Pharmacokinetics of Pretomanid.
    Antimicrob Agents Chemother. 2019 Aug 12. pii: AAC.00907.
    PubMed     Abstract available
    
    
    
78. PARK Y, Ahn YM, Jonnala S, Oh S, et al
    Inhibition of CorA dependent Magnesium Homeostasis is cidal in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2019 Aug 5. pii: AAC.01006.
    PubMed     Abstract available
    
    
    
79. TUCKER EW, Pieterse L, Zimmerman MD, Udwadia ZF, et al
    Delamanid Central Nervous System Pharmacokinetics in Tuberculous Meningitis in Rabbits and Humans.
    Antimicrob Agents Chemother. 2019 Aug 5. pii: AAC.00913.
    PubMed     Abstract available
    
    
    July 2019
80. LI H, Salinger DH, Everitt D, Li M, et al
    Long-Term Effects on QT prolongation of Pretomanid, Alone and in Combinations, in Patients with Tuberculosis.
    Antimicrob Agents Chemother. 2019 Jul 29. pii: AAC.00445.
    PubMed     Abstract available
    
    
    
81. SARATHY JP, Ragunathan P, Shin J, Cooper CB, et al
    TBAJ-876 retains Bedaquiline's activity against subunit c and of Mycobacterium tuberculosis F-ATP synthase.
    Antimicrob Agents Chemother. 2019 Jul 29. pii: AAC.01191.
    PubMed     Abstract available
    
    
    
82. KORYCKA-MACHALA M, Viljoen A, Pawelczyk J, Borowka P, et al
    1H-benzo[d]imidazole derivatives affect MmpL3 in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2019 Jul 22. pii: AAC.00441.
    PubMed     Abstract available
    
    
    
83. ENIMIL A, Antwi S, Yang H, Dompreh A, et al
    Effect of first-line antituberculosis therapy on nevirapine pharmacokinetics in children younger than 3 years old.
    Antimicrob Agents Chemother. 2019 Jul 22. pii: AAC.00839.
    PubMed     Abstract available
    
    
    
84. KIDWAI S, Bouzeyen R, Chakraborti S, Khare N, et al
    NU-6027 inhibits growth of Mycobacterium tuberculosis by targeting Protein Kinase D and Protein Kinase G.
    Antimicrob Agents Chemother. 2019 Jul 8. pii: AAC.00996.
    PubMed     Abstract available
    
    
    
85. GHODOUSI A, Rizvi AH, Baloch AQ, Ghafoor A, et al
    Acquisition of cross-resistance to Bedaquiline and Clofazimine following treatment for Tuberculosis in Pakistan.
    Antimicrob Agents Chemother. 2019 Jul 1. pii: AAC.00915.
    PubMed     Abstract available
    
    
    June 2019
86. REHBERG N, Omeje E, Ebada SS, van Geelen L, et al
    3-O-Methyl-alkylgallates inhibit fatty acid desaturation in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2019 Jun 17. pii: AAC.00136.
    PubMed     Abstract available
    
    
    
87. TENERO D, Derimanov G, Carlton A, Tonkyn J, et al
    First time in human (FTIH) study and prediction of early bactericidal activity for GSK3036656, a potent Leucyl - tRNA synthetase inhibitor for tuberculosis treatment.
    Antimicrob Agents Chemother. 2019 Jun 10. pii: AAC.00240.
    PubMed     Abstract available
    
    
    
88. MCNEIL MB, Cook GM
    Utilization of CRISPR interference to validate MmpL3 as a drug target in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2019 Jun 3. pii: AAC.00629.
    PubMed     Abstract available
    
    
    
89. O'DONNELL MR, Larsen MH, Brown TS, Jain P, et al
    Erratum for O'Donnell et al., "Early Detection of Emergent Extensively Drug-Resistant Tuberculosis by Flow Cytometry-Based Phenotyping and Whole-Genome Sequencing".
    Antimicrob Agents Chemother. 2019;63.
    PubMed    
    
    
    May 2019
90. SUVICHAPANICH S, Wattanapokayakit S, Mushiroda T, Yanai H, et al
    Genome-Wide Association Study Confirming the Association of NAT2 with Susceptibility to Anti-tuberculosis Drug-Induced Liver Injury in Thai Patients.
    Antimicrob Agents Chemother. 2019 May 20. pii: AAC.02692.
    PubMed     Abstract available
    
    
    
91. SEIFERT M, Capparelli E, Catanzaro DG, Rodwell TC, et al
    Using Mycobacterium tuberculosis single nucleotide polymorphisms to predict fluoroquinolone treatment response.
    Antimicrob Agents Chemother. 2019 May 13. pii: AAC.00076.
    PubMed     Abstract available
    
    
    
92. ZHANG Y, Zhu H, Fu L, Wang B, et al
    Identifying regimens containing a new drug candidate TBI-166 against Mycobacterium tuberculosis in vitro and in vivo.
    Antimicrob Agents Chemother. 2019 May 6. pii: AAC.02496.
    PubMed     Abstract available
    
    
    
93. AL-SHAER MH, Alghamdi WA, Alsultan A, An G, et al
    Fluoroquinolones in drug-resistant tuberculosis: culture conversion and pharmacokinetic/pharmacodynamic target attainment to guide dose selection.
    Antimicrob Agents Chemother. 2019 May 6. pii: AAC.00279.
    PubMed     Abstract available
    
    
    
94. MALIK AA, Brooks MB, Siddiqui S, Fuad J, et al
    Pharmacokinetics of Levofloxacin in Children Treated for Exposure to Drug-Resistant Tuberculosis.
    Antimicrob Agents Chemother. 2019;63.
    PubMed     Abstract available
    
    
    
95. GHIMIRE S, Maharjan B, Jongedijk EM, Kosterink JGW, et al
    Evaluation of Saliva as a Potential Alternative Sampling Matrix for Therapeutic Drug Monitoring of Levofloxacin in Patients with Multidrug-Resistant Tuberculosis.
    Antimicrob Agents Chemother. 2019;63.
    PubMed     Abstract available
    
    
    April 2019
96. VAN DEN ELSEN SHJ, Sturkenboom MGG, Akkerman OW, Manika K, et al
    Limited sampling strategies using linear regression and the Bayesian approach for therapeutic drug monitoring of moxifloxacin in tuberculosis patients.
    Antimicrob Agents Chemother. 2019 Apr 22. pii: AAC.00384.
    PubMed     Abstract available
    
    
    
97. GHODOUSI A, Tagliani E, Karunaratne E, Niemann S, et al
    Isoniazid resistance in Mycobacterium tuberculosis is a heterogeneous phenotype comprised of overlapping MIC distributions with different underlying resistance mechanisms.
    Antimicrob Agents Chemother. 2019 Apr 22. pii: AAC.00092.
    PubMed     Abstract available
    
    
    
98. IACOBINO A, Giannoni F, Pardini M, Piccaro G, et al
    The combination rifampin-nitazoxanide, but not rifampin-isoniazid-pyrazinamide-ethambutol, kills dormant Mycobacterium tuberculosis in hypoxia at neutral pH.
    Antimicrob Agents Chemother. 2019 Apr 22. pii: AAC.00273.
    PubMed     Abstract available
    
    
    
99. LUN S, Tasneen R, Chaira T, Stec J, et al
    Advancing the therapeutic potential of indoleamides for tuberculosis.
    Antimicrob Agents Chemother. 2019 Apr 22. pii: AAC.00343.
    PubMed     Abstract available
    
    
    
100. LOISEAU C, Brites D, Moser I, Coll F, et al
     Revised interpretation of the Hain Lifescience GenoType MTBC to differentiate Mycobacterium canettii and members of the M. tuberculosis complex.
     Antimicrob Agents Chemother. 2019 Apr 8. pii: AAC.00159.
     PubMed     Abstract available
     
     
     
101. BERUBE BJ, Russell D, Castro L, Choi SR, et al
     Novel MenA inhibitors are bactericidal against Mycobacterium tuberculosis and synergize with electron-transport chain inhibitors.
     Antimicrob Agents Chemother. 2019 Apr 8. pii: AAC.02661.
     PubMed     Abstract available
     
     
     
102. RANJAN R, Srivastava A, Bharti R, Roy T, et al
     Preclinical development of inhalable D-cycloserine and ethionamide to overcome pharmacokinetic interaction and enhance efficacy against Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2019 Apr 8. pii: AAC.00099.
     PubMed     Abstract available
     
     
     
103. SAINI V, Ammerman NC, Chang YS, Tasneen R, et al
     Treatment-shortening effect of a novel regimen combining high-dose rifapentine and clofazimine in pathologically distinct mouse models of tuberculosis.
     Antimicrob Agents Chemother. 2019 Apr 1. pii: AAC.00388.
     PubMed     Abstract available
     
     
     March 2019
104. SEKAGGYA-WILTSHIRE C, Chirehwa M, Musaazi J, von Braun A, et al
     Low anti-tuberculosis drug concentrations in HIV-Tuberculosis co-infected adults with low body weight; is it time to update dosing guidelines?
     Antimicrob Agents Chemother. 2019 Mar 25. pii: AAC.02174.
     PubMed     Abstract available
     
     
     
105. SHI W, Cui P, Niu H, Zhang S, et al
     Introducing RpsA Point Mutations Delta438A and D123A into the Chromosome of M. tuberculosis Confirms their Role in Causing Resistance to Pyrazinamide.
     Antimicrob Agents Chemother. 2019 Mar 11. pii: AAC.02681.
     PubMed     Abstract available
     
     
     
106. ALGHAMDI WA, Alsultan A, Al-Shaer MH, An G, et al
     Cycloserine Population Pharmacokinetics and Pharmacodynamics in Patients with Tuberculosis.
     Antimicrob Agents Chemother. 2019 Mar 11. pii: AAC.00055.
     PubMed     Abstract available
     
     
     
107. XU J, Li SY, Almeida DV, Tasneen R, et al
     Contribution of pretomanid to novel regimens containing bedaquiline with either linezolid or moxifloxacin and pyrazinamide in murine models of tuberculosis.
     Antimicrob Agents Chemother. 2019 Mar 4. pii: AAC.00021.
     PubMed     Abstract available
     
     
     
108. ISMAIL N, Peters RPH, Ismail NA, Omar SV, et al
     Clofazimine Exposure In Vitro Selects Efflux Pump Mutants and Bedaquiline Resistance.
     Antimicrob Agents Chemother. 2019;63.
     PubMed     Abstract available
     
     
     
109. MUSTAZZOLU A, Venturelli L, Dinarelli S, Brown K, et al
     A Rapid Unraveling of the Activity and Antibiotic Susceptibility of Mycobacteria.
     Antimicrob Agents Chemother. 2019;63.
     PubMed     Abstract available
     
     
     February 2019
110. SARATHY J, Blanc L, Alvarez-Cabrera N, O'Brien P, et al
     Fluoroquinolone efficacy against tuberculosis is driven by penetration into lesions and activity against resident bacterial populations.
     Antimicrob Agents Chemother. 2019 Feb 25. pii: AAC.02516.
     PubMed     Abstract available
     
     
     
111. XU J, Wang B, Fu L, Zhu H, et al
     In vitro and in vivo activities of the riminophenazine TBI-166 against Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2019 Feb 19. pii: AAC.02155.
     PubMed     Abstract available
     
     
     
112. ROBERTSON GT, Ektnitphong VA, Scherman MS, McNeil MB, et al
     Efficacy and improved resistance potential of a cofactor-independent InhA inhibitor of Mycobacterium tuberculosis in a C3HeB/FeJ mouse model.
     Antimicrob Agents Chemother. 2019 Feb 11. pii: AAC.02071.
     PubMed     Abstract available
     
     
     
113. KAUSHIK A, Ammerman NC, Tyagi S, Saini V, et al
     Activity of a long-acting injectable bedaquiline formulation in a paucibacillary mouse model of latent tuberculosis infection.
     Antimicrob Agents Chemother. 2019 Feb 11. pii: AAC.00007.
     PubMed     Abstract available
     
     
     
114. GYGLI SM, Keller PM, Ballif M, Blochliger N, et al
     Whole genome sequencing for drug resistance profile prediction in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2019 Feb 4. pii: AAC.02175.
     PubMed     Abstract available
     
     
     January 2019
115. O'DONNELL MR, Larsen MH, Brown TS, Jain P, et al
     Early detection of emergent extensively drug resistant tuberculosis (XDR-TB) by flow cytometry-based phenotyping and whole genome sequencing.
     Antimicrob Agents Chemother. 2019 Jan 22. pii: AAC.01834.
     PubMed     Abstract available
     
     
     
116. GARCIA-PRATS AJ, Purchase SE, Osman M, Draper HR, et al
     Pharmacokinetics, safety, and dosing of novel pediatric levofloxacin dispersible tablets in children with multidrug-resistant tuberculosis exposure.
     Antimicrob Agents Chemother. 2019 Jan 22. pii: AAC.01865.
     PubMed     Abstract available
     
     
     
117. RUIZ P, Causse M, Vaquero M, Casal M, et al
     In vitro activity of Tedizolid against Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2019 Jan 22. pii: AAC.01939.
     PubMed     Abstract available
     
     
     
118. FRANCIS J, Zvada SP, Denti P, Hatherill M, et al
     Arylacetamide deacetylase (AADAC) gene polymorphism and HIV infection affect the exposure of Rifapentine: a population pharmacokinetics analysis.
     Antimicrob Agents Chemother. 2019 Jan 22. pii: AAC.01964.
     PubMed     Abstract available
     
     
     
119. WASSERMAN S, Denti P, Brust JCM, Tareq M, et al
     Linezolid pharmacokinetics in South African patients with drug resistant tuberculosis and a high prevalence of HIV co-infection.
     Antimicrob Agents Chemother. 2019 Jan 7. pii: AAC.02164.
     PubMed     Abstract available
     
     
     
120. GHAJAVAND H, Kargarpour Kamakoli M, Khanipour S, Pourazar Dizaji S, et al
     High Prevalence of Bedaquiline Resistance in Treatment-naive Tuberculosis Patients and Verapamil Effectiveness.
     Antimicrob Agents Chemother. 2019 Jan 2. pii: AAC.02530.
     PubMed     Abstract available
     
     
     
121. CHOULES MP, Wolf NM, Lee H, Anderson JR, et al
     Rufomycin Targets ClpC1 Proteolysis in Mycobacterium tuberculosis and M. abscessus.
     Antimicrob Agents Chemother. 2019 Jan 2. pii: AAC.02204.
     PubMed     Abstract available
     
     
     
122. KHALIL ZG, Hill TA, De Leon Rodriguez LM, Lohman RJ, et al
     Structure-activity relationships of wollamide cyclic hexapeptides with activity against drug-resistant and intracellular Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2019 Jan 2. pii: AAC.01773.
     PubMed     Abstract available
     
     
     
123. RICHARD M, Gutierrez AV, Viljoen A, Rodriguez-Rincon D, et al
     Mutations in the MAB_2299c TetR Regulator Confer Cross-Resistance to Clofazimine and Bedaquiline in Mycobacterium abscessus.
     Antimicrob Agents Chemother. 2018;63.
     PubMed     Abstract available
     
     
     November 2018
124. DEKKERS BGJ, Akkerman OW, Alffenaar JWC
     The role of therapeutic drug monitoring in treatment optimization in tuberculosis and diabetes mellitus co-morbidity.
     Antimicrob Agents Chemother. 2018 Nov 19. pii: AAC.02074.
     PubMed     Abstract available
     
     
     
125. VAN RIJN SP, Zuur MA, Anthony R, Wilffert B, et al
     Evaluation of carbapenems for multi/extensive-drug resistant Mycobacterium tuberculosis treatment.
     Antimicrob Agents Chemother. 2018 Nov 19. pii: AAC.01489.
     PubMed     Abstract available
     
     
     
126. ANDRES S, Groschel MI, Hillemann D, Merker M, et al
     A diagnostic algorithm to investigate pyrazinamide and ethambutol resistance in rifampicin resistant Mycobacterium tuberculosis isolates in a low incidence setting.
     Antimicrob Agents Chemother. 2018 Nov 19. pii: AAC.01798.
     PubMed     Abstract available
     
     
     
127. MEIKLE V, Mossberg AK, Mitra A, Hakansson AP, et al
     A protein complex from human milk enhances the activity of antibiotics and drugs against Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2018 Nov 12. pii: AAC.01846.
     PubMed     Abstract available
     
     
     
128. DE MIRANDA SILVA C, Hajihosseini A, Myrick J, Nole J, et al
     Effect of Moxifloxacin plus Pretomanid against Mycobacterium tuberculosis in Log-phase, Acid-phase and Non-Replicating-Persister (NRP)-phase in an in vitro Assay.
     Antimicrob Agents Chemother. 2018 Nov 5. pii: AAC.01695.
     PubMed     Abstract available
     
     
     
129. KWARA A, Yang H, Antwi S, Enimil A, et al
     Effect of rifampin/isoniazid-containing antituberculosis therapy on efavirenz pharmacokinetics in HIV-infected children aged 3 to 14 years old.
     Antimicrob Agents Chemother. 2018 Nov 5. pii: AAC.01657.
     PubMed     Abstract available
     
     
     
130. VILCHEZE C, Jacobs WR Jr
     Reply to Yew et al., "Vitamin C and Mycobacterium tuberculosis Persisters".
     Antimicrob Agents Chemother. 2018;62.
     PubMed    
     
     
     
131. YEW WW, Chang KC, Leung CC, Chan DP, et al
     Vitamin C and Mycobacterium tuberculosis Persisters.
     Antimicrob Agents Chemother. 2018;62.
     PubMed    
     
     
     October 2018
132. VAN DEN ELSEN SHJ, Sturkenboom MGG, van 't Boveneind-Vrubleuskaya N, Skrahina A, et al
     Population pharmacokinetic model and limited sampling strategies for personalized dosing of levofloxacin in tuberculosis patients.
     Antimicrob Agents Chemother. 2018 Oct 29. pii: AAC.01092.
     PubMed     Abstract available
     
     
     
133. MELIEF E, Bonnett SA, Zuniga ES, Parish T, et al
     Activation of 2,4-diaminoquinazoline in Mycobacterium tuberculosis by Rv3161c, a putative dioxygenase.
     Antimicrob Agents Chemother. 2018 Oct 15. pii: AAC.01505.
     PubMed     Abstract available
     
     
     
134. RYBNIKER J, Andreas Kohl T, Barilar I, Niemann S, et al
     No evidence for acquired mutations associated with cytochrome bc 1-inhibitor resistance in 13,559 clinical Mycobacterium tuberculosis complex isolates.
     Antimicrob Agents Chemother. 2018 Oct 15. pii: AAC.01317.
     PubMed     Abstract available
     
     
     September 2018
135. DOAN TN, Cao P, Emeto TI, McCaw JM, et al
     Predicting the Outcomes of New Short-Course Regimens for Multi-Drug Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modelling.
     Antimicrob Agents Chemother. 2018 Sep 24. pii: AAC.01487.
     PubMed     Abstract available
     
     
     
136. LOUIE A, Duncanson B, Myrick J, Maynard M, et al
     The Activity of Moxifloxacin against Acid-Phase and Non-Replicative Persister Phenotype Phase Mycobacterium tuberculosis in a Hollow Fiber Infection Model.
     Antimicrob Agents Chemother. 2018 Sep 24. pii: AAC.01470.
     PubMed     Abstract available
     
     
     
137. DIAN S, Yunivita V, Ganiem AR, Pramaesya T, et al
     A double-blinded randomised placebo-controlled phase II trial to evaluate high dose rifampicin for tuberculous meningitis: a dose finding study.
     Antimicrob Agents Chemother. 2018 Sep 17. pii: AAC.01014.
     PubMed     Abstract available
     
     
     August 2018
138. CAO R, Teskey G, Islamoglu H, Abrahem R, et al
     Characterizing the Effects of Glutathione as an Immunoadjuvant in the Treatment of Tuberculosis.
     Antimicrob Agents Chemother. 2018 Aug 20. pii: AAC.01132.
     PubMed     Abstract available
     
     
     
139. ALFARISI O, Mave V, Gaikwad S, Sahasrabudhe T, et al
     The effect of diabetes mellitus on the pharmacokinetics and pharmacodynamics of tuberculosis treatment.
     Antimicrob Agents Chemother. 2018 Aug 20. pii: AAC.01383.
     PubMed     Abstract available
     
     
     
140. LUPIEN A, Vocat A, Foo CS, Blattes E, et al
     An optimized background regimen for treatment of active tuberculosis with the next-generation benzothiazinone Macozinone (PBTZ169).
     Antimicrob Agents Chemother. 2018 Aug 20. pii: AAC.00840.
     PubMed     Abstract available
     
     
     
141. KANDLER JL, Mercante AD, Dalton TL, Ezewudo MN, et al
     Validation of novel Mycobacterium tuberculosis isoniazid resistance mutations not detectable by common molecular tests.
     Antimicrob Agents Chemother. 2018 Aug 6. pii: AAC.00974.
     PubMed     Abstract available
     
     
     
142. KOSER CU, Heyckendorf J, Andres S, Olaru ID, et al
     Reply to Dookie et al., "Whole-Genome Sequencing To Guide the Selection of Treatment for Drug-Resistant Tuberculosis".
     Antimicrob Agents Chemother. 2018;62.
     PubMed    
     
     
     
143. DOOKIE N, Naidoo K, Padayatchi N
     Whole-Genome Sequencing To Guide the Selection of Treatment for Drug-Resistant Tuberculosis.
     Antimicrob Agents Chemother. 2018;62.
     PubMed    
     
     
     July 2018
144. JAGIELSKI T, Bakula Z, Brzostek A, Minias A, et al
     Characterization of mutations conferring resistance to rifampicin in Mycobacterium tuberculosis clinical strains.
     Antimicrob Agents Chemother. 2018 Jul 30. pii: AAC.01093.
     PubMed     Abstract available
     
     
     
145. PELOQUIN CA, Phillips PPJ, Mitnick CD, Eisenach K, et al
     Increased Doses Lead to Higher Drug Exposures of Levofloxacin for the Treatment of Tuberculosis.
     Antimicrob Agents Chemother. 2018 Jul 16. pii: AAC.00770.
     PubMed     Abstract available
     
     
     
146. PITON J, Vocat A, Lupien A, Foo C, et al
     Structure-based drug design and characterization of sulfonyl-piperazine benzothiazinone inhibitors of DprE1 from Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2018 Jul 16. pii: AAC.00681.
     PubMed     Abstract available
     
     
     
147. PIETERMAN ED, Te Brake LHM, de Knegt GJ, van der Meijden A, et al
     Assessment of the additional value of verapamil to a moxifloxacin and linezolid combination regimen in a murine tuberculosis model.
     Antimicrob Agents Chemother. 2018 Jul 9. pii: AAC.01354.
     PubMed     Abstract available
     
     
     
148. AGUILAR-PEREZ C, Gracia B, Rodrigues L, Vitoria A, et al
     Synergy between circular bacteriocin AS-48 and ethambutol against Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2018 Jul 9. pii: AAC.00359.
     PubMed     Abstract available
     
     
     June 2018
149. RANCOITA PMV, Cugnata F, Gibertoni Cruz AL, Borroni E, et al
     Validating a 14-drug microtitre plate containing bedaquiline and delamanid for large-scale research susceptibility testing of Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2018 Jun 25. pii: AAC.00344.
     PubMed     Abstract available
     
     
     
150. HORITA Y, Alsultan A, Kwara A, Antwi S, et al
     Evaluation of the Adequacy of WHO revised Dosages of the First-Line Anti-Tuberculosis Drugs in Children with Tuberculosis using Population Pharmacokinetic Modeling and Simulations.
     Antimicrob Agents Chemother. 2018 Jun 18. pii: AAC.00008.
     PubMed     Abstract available
     
     
     
151. DE MIRANDA SILVA C, Hajihosseini A, Myrick J, Nole J, et al
     Effect of Linezolid plus Bedaquiline against Mycobacterium tuberculosis in Log-Phase, Acid-Phase and Non-Replicating-Persister (NRP)-Phase in an In vitro Assay.
     Antimicrob Agents Chemother. 2018 Jun 4. pii: AAC.00856.
     PubMed     Abstract available
     
     
     
152. DRUSANO GL, Myrick J, Maynard M, Nole J, et al
     Linezolid Kills Acid Phase and Non-replicative Persister Phase Mycobacterium tuberculosis in a Hollow Fiber Infection Model.
     Antimicrob Agents Chemother. 2018 Jun 4. pii: AAC.00221.
     PubMed     Abstract available
     
     
     May 2018
153. ZONG Z, Jing W, Shi J, Wen S, et al
     Comparison of in vitro activity and MIC distributions between the novel oxazolidinone delpazolid and linezolid against multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis in China.
     Antimicrob Agents Chemother. 2018 May 29. pii: AAC.00165.
     PubMed     Abstract available
     
     
     
154. SHOEN C, DeStefano M, Hafkin B, Cynamon M, et al
     In vitro and in vivo activity of contezolid (MRX-I) against Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2018 May 21. pii: AAC.00493.
     PubMed     Abstract available
     
     
     
155. YEW WW, Chang KC, Chan DP
     Oxidative Stress and First-Line Antituberculosis Drug-Induced Hepatotoxicity.
     Antimicrob Agents Chemother. 2018 May 21. pii: AAC.02637.
     PubMed     Abstract available
     
     
     
156. AMMERMAN NC, Swanson RV, Bautista EM, Almeida DV, et al
     Impact of Clofazimine Dosing on Treatment-Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis.
     Antimicrob Agents Chemother. 2018 May 7. pii: AAC.00636.
     PubMed     Abstract available
     
     
     
157. KAUFMANN SHE
     Indole Propionic Acid: a Small Molecule Links between Gut Microbiota and Tuberculosis.
     Antimicrob Agents Chemother. 2018;62.
     PubMed    
     
     
     April 2018
158. SHI W, Chen J, Zhang S, Zhang W, et al
     Identification of novel mutations in LprG (rv1411c), rv0521,rv3630, rv0010c, ppsC,cyp128 associated with pyrazinoic acid/pyrazinamide resistance in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2018 Apr 23. pii: AAC.00430.
     PubMed     Abstract available
     
     
     
159. BOOT M, Commandeur S, Subudhi AK, Bahira M, et al
     Accelerating early anti-tuberculosis drug discovery by creating mycobacterial indicator strains that predict mode of action.
     Antimicrob Agents Chemother. 2018 Apr 16. pii: AAC.00083.
     PubMed     Abstract available
     
     
     
160. ZHENG H, Williams JT, Coulson GB, Haiderer ER, et al
     HC2091 kills Mycobacterium tuberculosis by targeting the MmpL3 mycolic acid transporter.
     Antimicrob Agents Chemother. 2018 Apr 16. pii: AAC.02459.
     PubMed     Abstract available
     
     
     
161. LIU Y, Pertinez H, Davies GR, Gillespie SH, et al
     Moxifloxacin replacement in contemporary tuberculosis drug regimens is ineffective against persistent Mycobacterium tuberculosis: Novel insights from the Cornell mouse model.
     Antimicrob Agents Chemother. 2018 Apr 16. pii: AAC.00190.
     PubMed     Abstract available
     
     
     
162. LYONS MA
     Modeling and Simulation of Pretomanid Pharmacokinetics in Pulmonary Tuberculosis Patients.
     Antimicrob Agents Chemother. 2018 Apr 16. pii: AAC.02359.
     PubMed     Abstract available
     
     
     
163. STEFAN MA, Ugur FS, Garcia GA
     SOURCE OF THE FITNESS DEFECT IN RIFAMYCIN-RESISTANT M. TUBERCULOSIS RNA POLYMERASE AND THE MECHANISM OF COMPENSATION BY MUTATIONS IN THE beta'-SUBUNIT.
     Antimicrob Agents Chemother. 2018 Apr 16. pii: AAC.00164.
     PubMed     Abstract available
     
     
     March 2018
164. ZIMENKOV D
     Mutation in luxR Family Transcriptional Regulator Rv0890c Is Not a Marker of Linezolid Resistance.
     Antimicrob Agents Chemother. 2018;62.
     PubMed    
     
     
     February 2018
165. GUPTA R, Felix CR, Akerman MP, Akerman KJ, et al
     Gold(III) macrocycles and chelates targeting Mycobacterium tuberculosis and Mycobacterium abscessus: evidence for inhibition of topoisomerase 1A.
     Antimicrob Agents Chemother. 2018 Feb 26. pii: AAC.01696.
     PubMed     Abstract available
     
     
     
166. CHEN C, Gardete S, Jansen RS, Shetty A, et al
     Verapamil targets membrane energetics in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2018 Feb 20. pii: AAC.02107.
     PubMed     Abstract available
     
     
     
167. HEMANTH KUMAR AK, Kumar A, Kannan T, Bhatia R, et al
     Pharmacokinetics of second-line anti-tuberculosis drugs in children with multidrug-resistant tuberculosis in India.
     Antimicrob Agents Chemother. 2018 Feb 20. pii: AAC.02410.
     PubMed     Abstract available
     
     
     
168. WEINER M, Gelfond J, Johnson-Pais TL, Engle M, et al
     Elevated Plasma Moxifloxacin Concentrations and SLCO1B1 g.-11187G>A Polymorphism in Adults with Pulmonary Tuberculosis.
     Antimicrob Agents Chemother. 2018 Feb 20. pii: AAC.01802.
     PubMed     Abstract available
     
     
     
169. ZUUR MA, Ghimire S, Bolhuis MS, Wessels AMA, et al
     The Pharmacokinetics of 2000 mg Ertapenem in Tuberculosis Patients.
     Antimicrob Agents Chemother. 2018 Feb 12. pii: AAC.02250.
     PubMed     Abstract available
     
     
     
170. CHEN Y, Yuan Z, Shen X, Wu J, et al
     Time to Multidrug-Resistant Tuberculosis Treatment Initiation in Association with Treatment Outcomes in Shanghai, China.
     Antimicrob Agents Chemother. 2018 Feb 5. pii: AAC.02259.
     PubMed     Abstract available
     
     
     
171. SAO EMANI C, Williams MJ, Wiid I, Baker B, et al
     Compounds with potential activity against Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2018 Feb 5. pii: AAC.02236.
     PubMed     Abstract available
     
     
     January 2018
172. WANG Q, Pang Y, Jing W, Liu Y, et al
     Clofazimine for Treatment of Pulmonary Extensively Drug-Resistant Tuberculosis in China.
     Antimicrob Agents Chemother. 2018 Jan 29. pii: AAC.02149.
     PubMed     Abstract available
     
     
     
173. HUO F, Luo J, Shi J, Zong Z, et al
     Increasing Prevalence of Rifampicin-Resistant Mycobacterium tuberculosis is Associated with the Transmission of Strains Harboring Compensatory Mutations in China: A 10-year Comparative Analysis.
     Antimicrob Agents Chemother. 2018 Jan 29. pii: AAC.02303.
     PubMed     Abstract available
     
     
     
174. DIJKSTRA JA, van der Laan T, Akkerman OW, Bolhuis MS, et al
     In vitro drug susceptibility of Mycobacterium tuberculosis for amikacin, kanamycin and capreomycin.
     Antimicrob Agents Chemother. 2018 Jan 8. pii: AAC.01724.
     PubMed     Abstract available
     
     
     
175. YU X, Zeng X, Shi W, Hu Y, et al
     The validation of Cycloserine efficacy in treatment of multidrug-resistant and extensively drug-resistant tuberculosis in Beijing, China.
     Antimicrob Agents Chemother. 2018 Jan 8. pii: AAC.01824.
     PubMed     Abstract available
     
     
     
176. VILCHEZE C, Kim J, Jacobs WR Jr
     Vitamin C potentiates the killing of Mycobacterium tuberculosis by the first-line tuberculosis drugs isoniazid and rifampicin in mice.
     Antimicrob Agents Chemother. 2018 Jan 3. pii: AAC.02165.
     PubMed     Abstract available
     
     
     
177. ALSULTAN A, Furin JJ, Du Bois J, van Brakel E, et al
     Erratum for Alsultan et al., "Population Pharmacokinetics of AZD-5847 in Adults with Pulmonary Tuberculosis".
     Antimicrob Agents Chemother. 2017;62.
     PubMed    
     
     
     December 2017
178. DOMPREH A, Tang X, Zhou J, Yang H, et al
     Effect of genetic variation of NAT2 on isoniazid, SLCO1B1, and CES2 on rifampin pharmacokinetics in Ghanaian children with tuberculosis.
     Antimicrob Agents Chemother. 2017 Dec 20. pii: AAC.02099.
     PubMed     Abstract available
     
     
     
179. AUNG WW, Ei PW, Nyunt WW, Htwe MM, et al
     Pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis clinical isolates in Myanmar.
     Antimicrob Agents Chemother. 2017 Dec 20. pii: AAC.01984.
     PubMed     Abstract available
     
     
     
180. SARATHY JP, Via LE, Weiner D, Blanc L, et al
     Extreme drug tolerance of Mycobacterium tuberculosis in caseum.
     Antimicrob Agents Chemother. 2017 Dec 4. pii: AAC.02266.
     PubMed     Abstract available
     
     
     
181. LEE H, Ahn S, Hwang NY, Jeon K, et al
     Limited Effect of Later-generation Fluoroquinolones in the Treatment of Ofloxacin-resistant and Moxifloxacin-susceptible Multidrug-resistant Tuberculosis.
     Antimicrob Agents Chemother. 2017 Dec 4. pii: AAC.01784.
     PubMed     Abstract available
     
     
     November 2017
182. DESHPANDE D, Srivastava S, Bendet P, Martin KR, et al
     On the antibacterial and sterilizing effect of benzylpenicillin in tuberculosis.
     Antimicrob Agents Chemother. 2017 Nov 27. pii: AAC.02232.
     PubMed     Abstract available
     
     
     
183. ABBADI BL, Villela AD, Rodrigues-Junior VS, Subtil FT, et al
     Revisiting activation of and the mechanism of resistance to the compound IQG-607 in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2017 Nov 20. pii: AAC.02222.
     PubMed     Abstract available
     
     
     
184. DENTI P, Garcia-Prats AJ, Draper HR, Wiesner L, et al
     Levofloxacin population pharmacokinetics in South African children treated for multidrug-resistant tuberculosis.
     Antimicrob Agents Chemother. 2017 Nov 13. pii: AAC.01521.
     PubMed     Abstract available
     
     
     
185. VAN DER LAAN LE, Garcia-Prats AJ, Schaaf HS, Tikiso T, et al
     Pharmacokinetics and drug-drug interactions of lopinavir/ritonavir administered with first and second-line antituberculosis drugs in HIV-infected children treated for multidrug-resistant tuberculosis.
     Antimicrob Agents Chemother. 2017 Nov 13. pii: AAC.00420.
     PubMed     Abstract available
     
     
     
186. HEYCKENDORF J, Andres S, Koser CU, Olaru ID, et al
     What is resistance? Impact of phenotypic versus molecular drug resistance testing on multi- and extensively drug-resistant tuberculosis therapy.
     Antimicrob Agents Chemother. 2017 Nov 13. pii: AAC.01550.
     PubMed     Abstract available
     
     
     October 2017
187. SUN Q, Xiao TY, Liu HC, Zhao XQ, et al
     Mutations within embCAB are associated with variable level of ethambutol resistance in Mycobacterium tuberculosis isolates from China.
     Antimicrob Agents Chemother. 2017 Oct 30. pii: AAC.01279.
     PubMed     Abstract available
     
     
     
188. WILLBY MJ, Wijkander M, Havumaki J, Johnson K, et al
     Detection of Mycobacterium tuberculosis pncA mutations by the NIPRO GenoscholarPZA-TB II as compared to conventional sequencing.
     Antimicrob Agents Chemother. 2017 Oct 30. pii: AAC.01871.
     PubMed     Abstract available
     
     
     
189. BERUBE BJ, Parish T
     Combinations of respiratory chain inhibitors have enhanced bactericidal activity against Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2017 Oct 23. pii: AAC.01677.
     PubMed     Abstract available
     
     
     
190. GENESTET C, Ader F, Pichat C, Lina G, et al
     Combined Antibacterial Effect of Isoniazid and Rifampicin on Four Mycobacterium tuberculosis Strains: in Vitro Experiments and Response-Surface Modeling.
     Antimicrob Agents Chemother. 2017 Oct 23. pii: AAC.01413.
     PubMed     Abstract available
     
     
     
191. XU J, Tasneen R, Peloquin CA, Almeida DV, et al
     Verapamil increases the bioavailability and efficacy of bedaquiline but not clofazimine in a murine model of tuberculosis.
     Antimicrob Agents Chemother. 2017 Oct 16. pii: AAC.01692.
     PubMed     Abstract available
     
     
     
192. DE WELZEN L, Eldholm V, Maharaj K, Manson AL, et al
     Whole transcriptome and genomic analysis of extensively drug-resistant Mycobacterium tuberculosis clinical isolates identifies downregulation of ethA as a mechanism of ethionamide resistance.
     Antimicrob Agents Chemother. 2017 Oct 9. pii: AAC.01461.
     PubMed     Abstract available
     
     
     
193. NAKATANI Y, Opel-Reading HK, Merker M, Machado D, et al
     Role of alanine racemase mutations in Mycobacterium tuberculosis D-cycloserine resistance.
     Antimicrob Agents Chemother. 2017 Oct 2. pii: AAC.01575.
     PubMed     Abstract available
     
     
     September 2017
194. XU W, DeJesus MA, Rucker N, Engelhart CA, et al
     Chemical genomic interaction profiling reveals determinants of intrinsic antibiotic resistance in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2017 Sep 11. pii: AAC.01334.
     PubMed     Abstract available
     
     
     
195. KIDWAI S, Park CY, Mawatwal S, Tiwari P, et al
     The dual mechanism of action of 5-Nitro-1,10-Phenanthroline against Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2017 Sep 11. pii: AAC.00969.
     PubMed     Abstract available
     
     
     
196. METCALFE JZ, Streicher E, Theron G, Colman RE, et al
     Mycobacterium tuberculosis subculture results in loss of potentially clinically relevant heteroresistance.
     Antimicrob Agents Chemother. 2017 Sep 11. pii: AAC.00888.
     PubMed     Abstract available
     
     
     
197. HUSZAR S, Singh V, Polcicova A, Barath P, et al
     N-Acetylglucosamine-1-phosphate transferase, WecA, as a validated drug target in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2017 Sep 5. pii: AAC.01310.
     PubMed     Abstract available
     
     
     
198. PARK SW, Tasneen R, Converse PJ, Nuermberger EL, et al
     Immunodeficiency and Intermittent Dosing Promote Acquired Rifamycin Monoresistance in Murine Tuberculosis.
     Antimicrob Agents Chemother. 2017 Sep 5. pii: AAC.01502.
     PubMed     Abstract available
     
     
     
199. PELOQUIN CA, Velasquez GE, Lecca L, Calderon RI, et al
     Erratum for Peloquin et al., "Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis".
     Antimicrob Agents Chemother. 2017;61.
     PubMed    
     
     
     
200. ARORA K, Ochoa-Montano B, Tsang PS, Blundell TL, et al
     Correction for Arora et al., "Respiratory Flexibility in Response to Inhibition of Cytochrome c Oxidase in Mycobacterium tuberculosis".
     Antimicrob Agents Chemother. 2017;61.
     PubMed    
     
     
     July 2017
201. MOOSA A, Lamprecht DA, Arora K, Barry CE 3rd, et al
     Susceptibility of Mycobacterium tuberculosis cytochrome bd oxidase mutants to compounds targeting the terminal respiratory oxidase, cytochrome c.
     Antimicrob Agents Chemother. 2017 Jul 31. pii: AAC.01338.
     PubMed     Abstract available
     
     
     
202. MCNEIL MB, Dennison D, Shelton C, Parish T, et al
     In vitro isolation and characterization of oxazolidinone resistant Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2017 Jul 31. pii: AAC.01296.
     PubMed     Abstract available
     
     
     
203. ALSULTAN A, Furin JJ, Du Bois J, van Brakel E, et al
     Population Pharmacokinetics of AZD-5847 in Adults with Pulmonary Tuberculosis.
     Antimicrob Agents Chemother. 2017 Jul 24. pii: AAC.01066.
     PubMed     Abstract available
     
     
     
204. MOURIK BC, de Knegt GJ, Verbon A, Mouton JW, et al
     Assessment of bactericidal drug activity and treatment outcome in a mouse tuberculosis model using a clinical Beijing strain.
     Antimicrob Agents Chemother. 2017 Jul 24. pii: AAC.00696.
     PubMed     Abstract available
     
     
     
205. PANG Y, Zong Z, Huo F, Jing W, et al
     In vitro drug susceptibility of bedaquiline, delamanid, linezolid, clofazimine, moxifloxacin, and gatifloxacin against extensively drug -resistant tuberculosis from Beijing, China.
     Antimicrob Agents Chemother. 2017 Jul 24. pii: AAC.00900.
     PubMed     Abstract available
     
     
     
206. YANG SS, Hu YB, Wang XD, Gao YR, et al
     Deletion of sigB Causes Increased Sensitivity to para-Aminosalicylic Acid and Sulfamethoxazole in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2017 Jul 17. pii: AAC.00551.
     PubMed     Abstract available
     
     
     
207. VAN RIJN SP, Srivastava S, Wessels MA, van Soolingen D, et al
     The sterilizing effect of ertapenem-clavulanate in a hollow fiber model of tuberculosis and implications on clinical dosing.
     Antimicrob Agents Chemother. 2017 Jul 10. pii: AAC.02039.
     PubMed     Abstract available
     
     
     
208. ZIMMERMAN M, Lestner J, Prideaux B, O'Brien P, et al
     Ethambutol partitioning in tuberculous pulmonary lesions explains its clinical efficacy.
     Antimicrob Agents Chemother. 2017 Jul 10. pii: AAC.00924.
     PubMed     Abstract available
     
     
     
209. PATEL N, O'Malley T, Zhang YK, Xia Y, et al
     A novel 6-benzyl ether benzoxaborole is active against Mycobacterium tuberculosis in vitro.
     Antimicrob Agents Chemother. 2017 Jul 3. pii: AAC.01205.
     PubMed     Abstract available
     
     
     June 2017
210. BABLISHVILI N, Tukvadze N, Shashkina E, Mathema B, et al
     The impact of gyrB and eis mutations in improving second-line drug resistance detection among Mycobacterium tuberculosis isolates from Georgia.
     Antimicrob Agents Chemother. 2017 Jun 19. pii: AAC.01921.
     PubMed     Abstract available
     
     
     
211. LI SY, Tasneen R, Tyagi S, Soni H, et al
     Bactericidal and sterilizing activity of a novel regimen with bedaquiline, pretomanid, moxifloxacin and pyrazinamide in a murine model of tuberculosis.
     Antimicrob Agents Chemother. 2017 Jun 19. pii: AAC.00913.
     PubMed     Abstract available
     
     
     
212. RAHMAN A, Ferdous SS, Ahmed S, Rahman SMM, et al
     Pyrazinamide susceptibility and pncA mutation profile of Mycobacterium tuberculosis among multi-drug resistant tuberculosis patients in Bangladesh.
     Antimicrob Agents Chemother. 2017 Jun 19. pii: AAC.00511.
     PubMed     Abstract available
     
     
     
213. CHIREHWA MT, McIlleron H, Rustomjee R, Mthiyane T, et al
     Pharmacokinetics of Pyrazinamide: optimising dosing regimens for drug-sensitive and -resistant tuberculosis.
     Antimicrob Agents Chemother. 2017 Jun 12. pii: AAC.00490.
     PubMed     Abstract available
     
     
     
214. RODRIGUES FELIX C, Gupta R, Geden S, Roberts J, et al
     Selective Killing Of Dormant Mycobacterium tuberculosis By Marine Natural Products.
     Antimicrob Agents Chemother. 2017 Jun 12. pii: AAC.00743.
     PubMed     Abstract available
     
     
     
215. ZHANG Y, Zhang J, Cui P, Zhang W, et al
     Identification of novel efflux proteins Rv0191, Rv3756c, Rv3008 and Rv1667c involved in pyrazinamide resistance in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2017 Jun 5. pii: AAC.00940.
     PubMed     Abstract available
     
     
     
216. SRIVASTAVA S, Magombedze G, Koeuth T, Sherman C, et al
     Linezolid dose that maximizes sterilizing effect while minimizing toxicity and resistance emergence for tuberculosis.
     Antimicrob Agents Chemother. 2017 Jun 5. pii: AAC.00751.
     PubMed     Abstract available
     
     
     
217. FOFANA MO, Dowdy DW
     Reply to Anthony et al., "Protecting Pyrazinamide, a Priority for Improving Outcomes in Multidrug-Resistant Tuberculosis Treatment".
     Antimicrob Agents Chemother. 2017;61.
     PubMed    
     
     
     
218. ANTHONY RM, Cynamon M, Hoffner S, Werngren J, et al
     Protecting Pyrazinamide, a Priority for Improving Outcomes in Multidrug-Resistant Tuberculosis Treatment.
     Antimicrob Agents Chemother. 2017;61.
     PubMed    
     
     
     May 2017
219. PELOQUIN CA, Velasquez GE, Lecca L, Calderon RI, et al
     Pharmacokinetic evidence to support increased doses of rifampin for tuberculosis: results from the HIRIF trial.
     Antimicrob Agents Chemother. 2017 May 30. pii: AAC.00038.
     PubMed     Abstract available
     
     
     
220. VAN'T BOVENEIND-VRUBLEUSKAYA N, Seuruk T, van Hateren K, van der Laan T, et al
     Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis patients.
     Antimicrob Agents Chemother. 2017 May 15. pii: AAC.00343.
     PubMed     Abstract available
     
     
     
221. SLOAN DJ, McCallum AD, Schipani A, Egan D, et al
     Genetic determinants of the pharmacokinetic variability of rifampicin in Malawian adults with pulmonary tuberculosis.
     Antimicrob Agents Chemother. 2017 May 1. pii: AAC.00210.
     PubMed     Abstract available
     
     
     
222. MOREIRA W, Santhanakrishnan S, Ngan GJY, Low CB, et al
     Towards Selective Mycobacterial ClpP1P2 Inhibitors with Reduced Activity against the Human Proteasome.
     Antimicrob Agents Chemother. 2017;61.
     PubMed     Abstract available
     
     
     April 2017
223. NJIRE M, Wang N, Wang B, Tan Y, et al
     Pyrazinoic Acid Inhibits a Bifunctional Enzyme in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2017 Apr 24. pii: AAC.00070.
     PubMed     Abstract available
     
     
     
224. VISWANATHAN G, Yadav S, Raghunand TR
     Identification of mycobacterial genes involved in antibiotic sensitivity - Implications in the treatment of tuberculosis with beta-lactam containing regimens.
     Antimicrob Agents Chemother. 2017 Apr 24. pii: AAC.00425.
     PubMed     Abstract available
     
     
     
225. OLLIARO PL, Merle C, Mthiyane T, Bah B, et al
     Analysis of the effects on the QT interval of a gatifloxacin-containing regimen versus standard treatment of pulmonary tuberculosis.
     Antimicrob Agents Chemother. 2017 Apr 24. pii: AAC.01834.
     PubMed     Abstract available
     
     
     
226. DANELISHVILI L, Shulzhenko N, Chinison JJJ, Babrak L, et al
     Mycobacterium tuberculosis proteome response to anti-tuberculosis compounds reveals metabolic "escape" pathways that prolong bacterial survival.
     Antimicrob Agents Chemother. 2017 Apr 17. pii: AAC.00430.
     PubMed     Abstract available
     
     
     
227. JANG J, Kim R, Woo M, Jeong J, et al
     Efflux attenuates the anti-bacterial activity of Q203 in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2017 Apr 17. pii: AAC.02637.
     PubMed     Abstract available
     
     
     
228. KEMPKER RR, Heinrichs MT, Nikolaishvili K, Sabulua I, et al
     Lung Tissue Concentrations of Pyrazinamide among Patients with Drug-Resistant Pulmonary Tuberculosis.
     Antimicrob Agents Chemother. 2017 Apr 3. pii: AAC.00226.
     PubMed     Abstract available
     
     
     
229. CHEN X, Hashizume H, Tomishige T, Nakamura I, et al
     Delamanid Kills Dormant Mycobacteria in Vitro and in the Guinea Pig Model of Tuberculosis.
     Antimicrob Agents Chemother. 2017 Apr 3. pii: AAC.02402.
     PubMed     Abstract available
     
     
     
230. VAN RIJN SP, Zuur MA, van Altena R, Akkerman OW, et al
     Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant Tuberculosis.
     Antimicrob Agents Chemother. 2017;61.
     PubMed     Abstract available
     
     
     March 2017
231. XU J, Wang B, Hu M, Huo F, et al
     Primary clofazimine and bedaquiline resistance among isolates from patients with multidrug-resistant tuberculosis.
     Antimicrob Agents Chemother. 2017 Mar 20. pii: AAC.00239.
     PubMed     Abstract available
     
     
     
232. ALSULTAN A, Savic R, Dooley KE, Weiner M, et al
     Population Pharmacokinetics of Pyrazinamide in Patients with Tuberculosis.
     Antimicrob Agents Chemother. 2017 Mar 13. pii: AAC.02625.
     PubMed     Abstract available
     
     
     
233. VELASQUEZ GE, Calderon RI, Mitnick CD, Becerra MC, et al
     Erratum for Velasquez et al., Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients with Multidrug-Resistant Tuberculosis.
     Antimicrob Agents Chemother. 2017;61.
     PubMed    
     
     
     February 2017
234. RAMACHANDRAN G, Kumar AK, Chandrasekaran V, Kannan T, et al
     Factors influencing tuberculosis treatment outcome in adult patients treated with thrice-weekly regimens in India.
     Antimicrob Agents Chemother. 2017 Feb 27. pii: AAC.02464.
     PubMed     Abstract available
     
     
     
235. ROBERTS O, Khoo S, Owen A, Siccardi M, et al
     Interaction of Rifampicin and Darunavir/Ritonavir or Darunavir/Cobicistat In Vitro.
     Antimicrob Agents Chemother. 2017 Feb 13. pii: AAC.01776.
     PubMed     Abstract available
     
     
     
236. KAYIGIRE XA, Friedrich SO, van der Merwe L, Diacon AH, et al
     Acquisition of rifampin resistance in pulmonary tuberculosis.
     Antimicrob Agents Chemother. 2017 Feb 6. pii: AAC.02220.
     PubMed     Abstract available
     
     
     
237. CHOI SR, Britigan BE, Narayanasamy P
     Ga(III) Nanoparticles Inhibit Growth of Both TB and HIV and Release of IL-6 and IL-8 in Co-Infected Macrophages.
     Antimicrob Agents Chemother. 2017 Feb 6. pii: AAC.02505.
     PubMed     Abstract available
     
     
     January 2017
238. AJILEYE A, Alvarez N, Merker M, Walker TM, et al
     Some synonymous and non-synonymous gyrA mutations in Mycobacterium tuberculosis lead to systematic false-resistance results to fluoroquinolones with the Hain GenoType MTBDRsl assays.
     Antimicrob Agents Chemother. 2017 Jan 30. pii: AAC.02169.
     PubMed     Abstract available
     
     
     
239. DE JAGER V, van der Merwe L, Venter A, Donald PR, et al
     Time trends in sputum mycobacterial load and 2-day bactericidal activity of INH-containing anti-tuberculosis therapies.
     Antimicrob Agents Chemother. 2017 Jan 30. pii: AAC.02088.
     PubMed     Abstract available
     
     
     
240. KUMAR P, Kaushik A, Bell D, Chauhan V, et al
     Mutation in an unannotated protein confers carbapenem resistance in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2017 Jan 9. pii: AAC.02234.
     PubMed     Abstract available
     
     
     
241. VAN ALTENA R, Dijkstra JA, van der Meer ME, Borjas Howard JF, et al
     Reduced chance of hearing loss associated with Therapeutic Drug Monitoring of Aminoglycosides in the treatment of Multidrug Resistant Tuberculosis.
     Antimicrob Agents Chemother. 2017 Jan 9. pii: AAC.01400.
     PubMed     Abstract available
     
     
     
242. SCHUMP MD, Fox DM, Bertozzi CR, Riley LW, et al
     Subcellular Partitioning and Intra-Macrophage Selectivity of Antimicrobial Compounds Against Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2017 Jan 4. pii: AAC.01639.
     PubMed     Abstract available
     
     
     December 2016
243. IACOBINO A, Piccaro G, Giannoni F, Mustazzolu A, et al
     Mycobacterium tuberculosis is selectively killed by rifampin and rifapentine in hypoxia at neutral pH.
     Antimicrob Agents Chemother. 2016 Dec 19. pii: AAC.02296.
     PubMed     Abstract available
     
     
     
244. FOFANA MO, Shrestha S, Knight GM, Cohen T, et al
     Role of pyrazinamide in the emergence of extensively drug-resistant tuberculosis: a multi-strain mathematical model.
     Antimicrob Agents Chemother. 2016 Dec 12. pii: AAC.00498.
     PubMed     Abstract available
     
     
     
245. PANG Y, Zhang Z, Wang Y, Wang S, et al
     Genotyping and prevalence of pyrazinamide- and moxifloxacin-resistant tuberculosis in China, 2000-2010: findings from the national survey data.
     Antimicrob Agents Chemother. 2016 Dec 5. pii: AAC.02170.
     PubMed     Abstract available
     
     
     November 2016
246. BROSSIER F, Pham A, Bernard C, Aubry A, et al
     Molecular investigation of resistance to second line injectable drugs in multidrug-resistant clinical isolates of Mycobacterium tuberculosis in France.
     Antimicrob Agents Chemother. 2016 Nov 28. pii: AAC.01299.
     PubMed     Abstract available
     
     
     
247. SEBASTIAN J, Swaminath S, Nair RR, Jakkala K, et al
     De Novo Emergence of Genetically Resistant Mutants of Mycobacterium tuberculosis from the Persistence Phase Cells formed against Antituberculosis Drugs In Vitro.
     Antimicrob Agents Chemother. 2016 Nov 28. pii: AAC.01343.
     PubMed     Abstract available
     
     
     
248. YEE M, Gopal P, Dick T
     Missense mutations in the unfoldase ClpC1 of the caseinolytic protease complex are associated with pyrazinamide resistance in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2016 Nov 21. pii: AAC.02342.
     PubMed     Abstract available
     
     
     
249. ROSEN BC, Dillon NA, Peterson ND, Minato Y, et al
     Long-Chain Fatty Acyl-CoA Ligase FadD2 Mediates Intrinsic Pyrazinamide Resistance in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2016 Nov 14. pii: AAC.02130.
     PubMed     Abstract available
     
     
     
250. ANTWI S, Yang H, Enimil A, Sarfo AM, et al
     Pharmacokinetics of the First-line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with and without HIV Coinfection.
     Antimicrob Agents Chemother. 2016 Nov 14. pii: AAC.01701.
     PubMed     Abstract available
     
     
     
251. ALFFENAAR JC, Akkerman OW, van Hest R
     Statin Adjunctive Therapy for Tuberculosis Treatment.
     Antimicrob Agents Chemother. 2016;60:7004.
     PubMed    
     
     
     October 2016
252. PHOLWAT S, Stroup S, Heysell S, Ogarkov O, et al
     Eis C-14G and C-15G mutations do not confer kanamycin resistance in M. tuberculosis.
     Antimicrob Agents Chemother. 2016 Oct 10. pii: AAC.01775.
     PubMed     Abstract available
     
     
     September 2016
253. WANG X, Yang S, Gu J, Deng J, et al
     Mycobacterium tuberculosis arylamine N-acetyltransferase acetylates and thus inactivates para-aminosalicylic acid.
     Antimicrob Agents Chemother. 2016 Sep 26. pii: AAC.01312.
     PubMed     Abstract available
     
     
     
254. LI Y, Wang Y, Zhang Z, Gao H, et al
     Association between embB Codon 306 Mutations, Phenotypic Resistance Profiles and Genotypic Characterization in Clinical Mycobacterium tuberculosis Isolates from Hebei, China.
     Antimicrob Agents Chemother. 2016 Sep 26. pii: AAC.00532.
     PubMed     Abstract available
     
     
     
255. VELASQUEZ GE, Calderon RI, Mitnick CD, Becerra MC, et al
     Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in MDR-TB Patients.
     Antimicrob Agents Chemother. 2016 Sep 6. pii: AAC.00632.
     PubMed     Abstract available
     
     
     May 2016
256. NIGHTINGALE S, Chau TT, Fisher M, Nelson M, et al
     Efavirenz and metabolites in CSF; relationship with CYP2B6 c.516G>T genotype and perturbed blood-brain barrier due to tuberculous meningitis.
     Antimicrob Agents Chemother. 2016 May 9. pii: AAC.00280.
     PubMed     Abstract available
     
     
     January 2016
257. BEKKER A, Schaaf HS, Draper HR, van der Laan L, et al
     The pharmacokinetics of rifampicin, isoniazid, pyrazinamide and ethambutol in infants dosed at revised WHO-recommended treatment guidelines.
     Antimicrob Agents Chemother. 2016 Jan 25. pii: AAC.02600.
     PubMed     Abstract available
     
     
     November 2015
258. CHIREHWA MT, Rustomjee R, Mthiyane T, Onyebujoh P, et al
     Model-based evaluation of higher doses of rifampicin using a semi-mechanistic model incorporating auto-induction and saturation of hepatic extraction.
     Antimicrob Agents Chemother. 2015 Nov 9. pii: AAC.01830.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Tuberculosis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: